MedTrace Logo

Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)

NCT03056482 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-04-03

No results posted yet for this study

Summary

Cannabis Hyperemesis Syndrome (CHS) has become a well-documented syndrome since 2004 and is expected to increase in prevalence with continuing liberalization of marijuana and recognition of the disease. Regardless of whether the association with heavy cannabis use is recognized, there is well-documented resistance to traditional anti-emetic treatment. Given promising reports of the use of intravenous haloperidol, a randomized controlled trial comparing it to the commonly administered anti-emetic ondansetron will contribute to the management of CHS

Conditions

  • Cannabis Use Disorder

Interventions

DRUG

Ondansetron 8mg

Ondansetron 8 MG prepared in a 100 mL normal saline min-bag

DRUG

Haloperidol 0.05mg/kg

Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag

DRUG

Haloperidol 0.1mg/kg

Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag

Sponsors & Collaborators

  • Dr. Marco L.A. Sivilotti

    lead OTHER

Principal Investigators

  • Marco LA Sivilotti, MD, MSc · Dept. of Emergency Medicine, Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-21
Primary Completion
2019-06-30
Completion
2019-07-07

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03056482 on ClinicalTrials.gov